Table I.
Association between clinical/pathological features and preoperative PSADT in 204 patients with clinically localized prostate cancer.
| Variable | Frequency, no. of patients (%) | PSADT (months), median (range) |
|---|---|---|
| Last measured serum PSA level prior to surgery (ng/ml), median (range) | P<0.0005 | |
| <4.0 | 9 (4.4) | 19.38 (0–95.5) |
| 4.1–10.0 | 130 (63.7) | 7.76 (−28.2–286) |
| 10.1–20.0 | 43 (22.1) | 4.02 (−9.08–34.5) |
| >20 | 22 (10.8) | 1.25 (−5.0–20.6) |
| Clinical stage | P=0.471 | |
| T1c | 155 (76.0) | 6.0 (−28.1–286) |
| T2a | 29 (14.2) | 3.63 (−9.08–44.3) |
| T2b | 12 (5.9) | 8.21 (0.7–82.4) |
| T2c | 6 (2.9) | 1.61 (0–16.9) |
| T3a | 2 (1.0) | 5.1 (0–10.3) |
| Risk group | P<0.0005 | |
| Low | 56 (27.4) | 9.47 (−6.5–95.5) |
| Intermediate | 86 (42.2) | 5.91 (−28.1–286) |
| High | 62 (30.4) | 3.58 (−5–107) |
| Pathological stage | P=0.01 | |
| pT2 | 121 (59.3) | 6.63 (−28.1–286) |
| pT3a | 64 (31.4) | 5.13 (−4.5–83.2) |
| pT3b | 16 (7.8) | 3.23 (−0.2–20.5) |
| pN+ | 3 (1.5) | 1.13 (0.6–8.0) |
| Specimen Gleason score | P=0.098 | |
| 4–6 | 55 (27.0) | 8.86 (−9.0–83.2) |
| 7 | 94 (46.0) | 4.59 (−28.1–286) |
| 8–10 | 55 (27.0) | 6.0 (−4.2–26.7) |
PSADT, prostate-specific antigen doubling time.